Literature DB >> 26419447

Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors.

Daniel Bertrand1, Chih-Hung L Lee2, Dorothy Flood2, Fabrice Marger2, Diana Donnelly-Roberts2.   

Abstract

Progress in the fields of neuroscience and molecular biology has identified the forebrain cholinergic system as being important in many higher order brain functions. Further analysis of the genes encoding the nicotinic acetylcholine receptors (nAChRs) has highlighted, in particular, the role of α7 nAChRs in these higher order brain functions as evidenced by their peculiar physiologic and pharmacological properties. As this receptor has gained the attention of scientists from academia and industry, our knowledge of its roles in various brain and bodily functions has increased immensely. We have also seen the development of small molecules that have further refined our understanding of the roles of α7 nAChRs, and these molecules have begun to be tested in clinical trials for several indications. Although a large body of data has confirmed a role of α7 nAChRs in cognition, the translation of small molecules affecting α7 nAChRs into therapeutics has to date only progressed to the stage of testing in clinical trials. Notably, however, most recent human genetic and biochemical studies are further underscoring the crucial role of α7 nAChRs and associated genes in multiple organ systems and disease states. The aim of this review is to discuss our current knowledge of α7 nAChRs and their relevance as a target in specific functional systems and disease states.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419447     DOI: 10.1124/pr.113.008581

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  42 in total

1.  Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.

Authors:  Nicole A Horenstein; Roger L Papke; Abhijit R Kulkarni; Ganesh U Chaturbhuj; Clare Stokes; Khan Manther; Ganesh A Thakur
Journal:  J Biol Chem       Date:  2016-01-07       Impact factor: 5.157

2.  S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway.

Authors:  Wenxiang Fan; Ying Zhang; Xiaomin Li; Chi Xu
Journal:  Neurochem Res       Date:  2021-01-22       Impact factor: 3.996

3.  Effect of nicotine on placental ischemia-induced complement activation and hypertension in the rat.

Authors:  Connor F Laule; Cameron R Wing; Evan J Odean; Jacob A Wilcox; Jeffrey S Gilbert; Jean F Regal
Journal:  J Immunotoxicol       Date:  2017-12       Impact factor: 3.000

4.  Heteromeric Neuronal Nicotinic Acetylcholine Receptors with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators.

Authors:  Clare Stokes; Sumanta Garai; Abhijit R Kulkarni; Lucas N Cantwell; Colleen M Noviello; Ryan E Hibbs; Nicole A Horenstein; Khalil A Abboud; Ganesh A Thakur; Roger L Papke
Journal:  J Pharmacol Exp Ther       Date:  2019-06-07       Impact factor: 4.030

5.  CHRNA7 copy number gains are enriched in adolescents with major depressive and anxiety disorders.

Authors:  Madelyn A Gillentine; Ricardo Lozoya; Jiani Yin; Christopher M Grochowski; Janson J White; Christian P Schaaf; Chadi A Calarge
Journal:  J Affect Disord       Date:  2018-07-11       Impact factor: 4.839

6.  Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine.

Authors:  J A Duce; X Zhu; L H Jacobson; P M Beart
Journal:  Br J Pharmacol       Date:  2019-09       Impact factor: 8.739

Review 7.  Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.

Authors:  Alan S Lewis; Gerrit I van Schalkwyk; Michael H Bloch
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-01-05       Impact factor: 5.067

Review 8.  Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.

Authors:  Jason R Tregellas; Korey P Wylie
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

9.  Longitudinal PET Imaging of α7 Nicotinic Acetylcholine Receptors with [18F]ASEM in a Rat Model of Parkinson's Disease.

Authors:  Steven Vetel; Johnny Vercouillie; Frédéric Buron; Jackie Vergote; Clovis Tauber; Julie Busson; Gabrielle Chicheri; Sylvain Routier; Sophie Sérrière; Sylvie Chalon
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

10.  Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3.

Authors:  Dong-Jie Li; Jie Tong; Fei-Yan Zeng; Mengqi Guo; Yong-Hua Li; Hongbo Wang; Pei Wang
Journal:  Br J Pharmacol       Date:  2018-11-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.